Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116)

Gynecologic Oncology

Volumn 89, Issue 1, 2003, Pages 129-133

  Oza, A M ^a   Elit, L ^b   Swenerton, K ^c   Faught, W ^d   Ghatage, P ^e   Carey, M ^f   McIntosh, L ^h   Dorr, A ^g   Holmlund, J T ^g   Eisenhauer, E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Vancouver Cancer Centre   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f London Regional Cancer Centre   (United Kingdom)

^g ISIS PHARMACEUTICALS   (United States)

^h University Health Network ^*

Author keywords

c raf kinase; ISIS; Ovarian cancer; Phase II trial

Indexed keywords

CGP 69846A;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BREATHING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; LETHARGY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TOXICITY;

EID: 0037385301     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00144-0     Document Type: Article

References (23)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 1998. Toronto, Canada; 1998.
2. Gadducci A., Brunetti I., Cosio S., et al. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer (Review). Anticancer Res. 17(6D):1997;4703-4708.
3. Eisenhauer E.A., Vermorken J.B. New drugs in gynecologic oncology. Curr Opin Oncol. 8:1996;408-414.
4. Eisenhauer E.A., Vermorken J.B., Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer an analysis of 704 patients . Ann Oncol. 8:1997;963-968.
5. Daum G., Eisenmann-Tappe I., Fries H.-W., Toppmair J., Rapp U.R. The ins and outs of raf kinases. TIPS. 19:1994;474.
6. Fu H., Zia K., Pallas D., et al. Interaction of the protein kinase raf-1 with 14-3-3 proteins. Science. 266:1994;126.
7. Crews C.M., Alessandrini A., Erikson R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 258:1992;478.
8. 21ras proteins bind to the amino terminal domain of c-raf-1. Nature. 364:1993;308.
9. Bos J.L. Ras oncogenes in human cancer a review . Cancer Res. 49:1989;4682.
10. Rapp U.R., Cleveland J.L., Bonner T.I., Storm S.M. The raf oncogenes. Reddy E.P., Skalka A.M., Curran T. The oncogene handbook. 1988;213 Elsevier Science, Amsterdam, The Netherlands.
11. Stanton V.P. Jr, Cooper G.M. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol. 7:1987;1171.
12. Kolch W. Meaningful relationships the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions . Biochem J. 351:2000;289-305. (Pt 2).
13. Langdon S., McPhillips F., Mullen P., Ritchie A., Smyth J., Monia B., Dorr A. Antisense Oligonucleotide (ISIS 5132) targeting of c-Raf kinase in ovarian cancer models. Proc Am Soc Clin Oncol. 20:2001;209a. (abstract).
14. Cunningham C.C., Holmlund J.T., Schiller J.H., Geary R.S., Kwoh T.J., Dorr A., Nemunaitis J. A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 6:2000;1626-1631.
15. Zee B., Melnychuk D., Dancey J., Eisenhauer E. Multinomial Phase II cancer trials incorporating response and early progression. J Biopharmaceutical Statistics. 9:1999;351-363.
16. Dent S., Zee B., Dancey J., Hanauske A., Wanders J., Eisenhauer E.A. Application of a new multivariate phase II stopping rule using response and early-progression. J Clin Oncol. 19:2001;785-791.
17. Meyer T., Rustin G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 82(9):2000;1535-1538.
18. O'Dwyer P.J., Stevenson J.P., Gallagher M., et al. c-raf-1 depletion and tumor responses in patients treated with c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res. 5:1999;3977-3982.
19. Britten R.A., Perdue S., Eshpeter A., Merriam D. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep. 7(4):2000;821-825.
20. Rasouli-Nia A., Liu D., Perdue S., Britten R.A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res. 4(5):1998;1111-1116.
21. Funato T., Kozawa K., Fujimaki S., Kaku M. Increased sensitivity to cytosine arabinoside in human leukemia by c-raf-1 antisense oligonucleotides. Anticancer Drugs. 4:2001;325-329.
22. Fidas P, Boral A, Shapiro G. Phase I and pharmacokinetic study of ISIS 5132 combined with carboplatin and paclitaxel for advanced non-small cell lung cancer. Tokyo, Japan: 9th world 58 conference on lung cancer; Sept 2000.
23. Stevenson J.P., Yao K.-S., Gallagher M., Friedland D., Mitchell E.P., Cassella A., Monia B., Yu R., Holmlund J., Dean N., Dorr F.A., Geary R., O'Dwyer P.J. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-kinase antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol. 17:1999;2227-2236.